SCHEMBL923552

SCHEMBL923552

CC(C)(C)OC(=O)NCC(=O)C1CCCCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 3/20 0.54
KMT2A Q03164 5/20 0.47
ALDH1A1 P00352 3/20 0.47
MEN1 O00255 3/20 0.47
TSHR P16473 1/20 0.47
BTK Q06187 1/20 0.45
GAA P10253 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42
TDP1 Q9NUW8 1/20 0.40
MAPT P10636 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
EPHX2 P34913 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
ITGB3 P05106 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23366831 0.98 EPHX1 (0.51) EPHX1KMT2AALDH1A1MEN1TSHR
SCHEMBL29618895 0.95 BTK (0.50) EPHX1KMT2AALDH1A1MEN1TSHR
SCHEMBL9931314 0.91 KMT2A (0.50) EPHX1KMT2AALDH1A1MEN1TSHR
SCHEMBL3763770 0.85 EPHX1 (0.60) EPHX1KMT2AALDH1A1MEN1TSHR
SCHEMBL27799448 0.84 KMT2A (0.45) EPHX1KMT2AALDH1A1MEN1TSHR
SCHEMBL23366889 0.84 KMT2A (0.45) EPHX1KMT2AALDH1A1MEN1TSHR
SCHEMBL3988278 0.83 EPHX1 (0.57) EPHX1KMT2AALDH1A1MEN1TSHR
SCHEMBL3091689 0.82 EPHX2 (0.42) EPHX1KMT2ASMN1; SMN2HSD17B10EPHX2
SCHEMBL29874054 0.82 BTK (0.43) EPHX1KMT2AALDH1A1MEN1TSHR
SCHEMBL23367354 0.82 BTK (0.43) EPHX1KMT2AALDH1A1MEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-4058446-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed
EP-3822265-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer AG (DE) 2021-05-19 EP disclosed
US-8258156-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2012-09-04 US disclosed
US-20110224185-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC, a Delaware Limited Company (BM) 2011-09-15 US disclosed
US-7875647-B2 and inverse agonist; 2-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole; obesity and obesity-related metabolic disorders GREEN CROSS CORPORATION (KR) 2011-01-25 US disclosed
EP-1966198-A1 2-AMINO-3,4-DIHYDRO-PYRIDOÝ3,4-D¨PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) JANSSEN PHARMACEUTICA N.V. (BE) 2008-09-10 EP disclosed
WO-2008105607-A1 HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS GREEN CROSS CORPORATION (KR) 2008-09-04 WO disclosed
US-20080207705-A1 Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists GREEN CROSS CORPORATION (KR) 2008-08-28 US disclosed
US-20080081812-A1 Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists GREEN CROSS CORPORATION (KR) 2008-04-03 US disclosed
WO-2007050612-A1 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 WO disclosed
WO-2004041795-A1 NOVEL INHIBITORS OF DIPEPTIDYL PEPTIDASE IV GUILFORD PHARMACEUTICALS INC. (US) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207705-A1 Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists CNR2, CNR1, GPR119 EPHX1 1493/4885KMT2A 1560/4885ALDH1A1 2785/4885
US-20110224185-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY GPR119, GPR65, GPR39 EPHX1 1428/4885KMT2A 3355/4885ALDH1A1 2341/4885
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAMTS1 EPHX1 1755/4885KMT2A 3100/4885ALDH1A1 2009/4885
US-20080081812-A1 Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists CNR2, CNR1, GPR119 EPHX1 1300/4885KMT2A 2129/4885ALDH1A1 2641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.